Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
[31]   Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey [J].
Mehmet Sinan Dal ;
Bahar Uncu Ulu ;
Ant Uzay ;
Olga Meltem Akay ;
Sevgi Beşışık ;
Mustafa Nuri Yenerel ;
Serhat Çelik ;
Leylagül Kaynar ;
Orhan Kemal Yücel ;
Burak Deveci ;
Mehmet Sönmez ;
Özgür Mehtap ;
Hüseyin Saffet Beköz ;
Cenk Sunu ;
Ozan Salim ;
Turgay Ulaş ;
Sami Kartı ;
Fevzi Altuntaş ;
Burhan Ferhanoğlu ;
Tülin Fırat Tuğlular .
Annals of Hematology, 2023, 102 :133-140
[32]   Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma [J].
Jurczak, W. ;
Zinzani, P. L. ;
Gaidano, G. ;
Goy, A. ;
Provencio, M. ;
Nagy, Z. ;
Robak, T. ;
Maddocks, K. ;
Buske, C. ;
Ambarkhane, S. ;
Winderlich, M. ;
Dirnberger-Hertweck, M. ;
Korolkiewicz, R. ;
Blum, K. A. .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1266-1272
[33]   Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma [J].
Frank Kroschinsky ;
Jan Moritz Middeke ;
Martin Janz ;
Georg Lenz ;
Mathias Witzens-Harig ;
Reda Bouabdallah ;
Paul La Rosée ;
Andreas Viardot ;
Gilles Salles ;
Seok Jin Kim ;
Tae Min Kim ;
Oliver Ottmann ;
Joerg Chromik ;
Anne-Marie Quinson ;
Ute von Wangenheim ;
Ute Burkard ;
Andreas Berk ;
Norbert Schmitz .
Investigational New Drugs, 2020, 38 :1472-1482
[34]   Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma [J].
Kroschinsky, Frank ;
Middeke, Jan Moritz ;
Janz, Martin ;
Lenz, Georg ;
Witzens-Harig, Mathias ;
Bouabdallah, Reda ;
La Rosee, Paul ;
Viardot, Andreas ;
Salles, Gilles ;
Kim, Seok Jin ;
Kim, Tae Min ;
Ottmann, Oliver ;
Chromik, Joerg ;
Quinson, Anne-Marie ;
von Wangenheim, Ute ;
Burkard, Ute ;
Berk, Andreas ;
Schmitz, Norbert .
INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) :1472-1482
[35]   Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis☆ [J].
Farooqi, Hanzala Ahmed ;
Ullah, Muhammad Saffi ;
Raza, Ahmed ;
Sadiq, Zain ;
Shaikh, Wardah Ali ;
Muhammad, Rahmah ;
Hussain, Muhammad Shoaib .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
[36]   A Phase 2 Study of Weekly Temsirolimus and Bortezomib for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Study [J].
Fenske, Timothy S. ;
Shah, Namrata M. ;
Kim, Kyung Mann ;
Saha, Sandeep ;
Zhang, Chong ;
Baim, Arielle E. ;
Farnen, John P. ;
Onitilo, Adedayo A. ;
Blank, Jules H. ;
Ahuja, Harish ;
Wassenaar, Tim ;
Qamar, Rubina ;
Mansky, Patrick ;
Traynor, Anne M. ;
Mattison, Ryan J. ;
Kahl, Brad S. .
CANCER, 2015, 121 (19) :3465-3471
[37]   Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [J].
Westin, Jason R. ;
McLaughlin, Peter ;
Romaguera, Jorge ;
Hagemeister, Fredrick B. ;
Pro, Barbara ;
Dang, Nam H. ;
Samaniego, Felipe ;
Rodriguez, Maria A. ;
Fayad, Luis ;
Oki, Yasuhiro ;
Fanale, Michelle ;
Fowler, Nathan ;
Nastoupil, Loretta ;
Feng, Lei ;
Loyer, Evelyn ;
Younes, Anas .
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (02) :177-184
[38]   Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma [J].
Bartlett, Nancy L. ;
Sehn, Laurie H. ;
Assouline, Sarit ;
Bosch, Francesc ;
Diefenbach, Catherine M. ;
Flinn, Ian ;
Hong, Jung Yong ;
Kim, Wonseog S. ;
Matasar, Matthew ;
Nastoupil, Loretta ;
Schuster, Stephen J. ;
Shadman, Mazyar ;
Yoon, Sung-Soo ;
Bender, Brendan ;
Chu, Wayne ;
Hernandez, Genevive ;
Kwan, Antonia ;
McCall, Bruce ;
Sison, Iris ;
Wang, Cunlin ;
Wei, Michael C. ;
Yin, Shen ;
Yousefi, Kasra ;
Budde, Elizabeth L. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S247-S247
[39]   A Multicenter Real-World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with a Polatuzumab Vedotin-Based Regimen in a Compassionate Use Program in Malaysia [J].
Wahid, S. Fadilah Abdul ;
Muhamad, Nor Asiah ;
Ismail, Nor Azimah ;
Rosli, Izzah Athirah ;
Kien, Chiang Su ;
Lim, Soo Min ;
Chew, Lee Ping ;
Kamini, Kirubamoorthy ;
Selvaratnam, Veena ;
Kori, Ahlam Naila ;
Seng, Teh Hiok ;
Ng, Soo-Chin .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2025,
[40]   The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan [J].
Fujita, Naoto ;
Mori, Tetsuya ;
Mitsui, Tetsuo ;
Inada, Hiroko ;
Horibe, Keizo ;
Tsurusawa, Masahito .
PEDIATRIC BLOOD & CANCER, 2008, 51 (02) :188-192
12345